Investor Relations

- 0.31
Day High
Day Low
11:06 AM ET on Dec 1, 2015
Stock price graph

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.

In July 2010, Momenta’s lead product (developed in collaboration with Sandoz) was approved as the first generic version of Lovenox® (Enoxaparin Sodium Injection). In April 2015, the company announced the FDA approval of once daily Glatopa™ 20 mg/mL (glatiramer acetate injection), a fully substitutable generic version of Copaxone® 20 mg/mL. Glatopa was also developed in collaboration with Sandoz. The company's development pipeline includes a biosimilar version of HUMIRA® (adalimumab) in collaboration with Baxalta, a portfolio of other early stage biosimilar programs, necuparanib (formerly M402), a novel oncology drug candidate currently in a Phase 2 trial, and a portfolio of novel autoimmune drug candidates.

View Annual Report and Proxy Material

View all »   RSSRecent Releases

Nov 13, 2015
Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study

Nov 10, 2015
Momenta Pharmaceuticals Announces U.S. Court of Appeals Decision to Remand Enoxaparin Case Back to District Court

Nov 6, 2015
Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences

Lovenox® is a registered trademark of Sanofi-Aventis. Copaxone® is a registered trademark of Teva Pharmaceutical Industries Ltd. Glatopa™ is a trademark of Novartis AG. HUMIRA® is a registered trademark of AbbVie.